

Getting Diagnosed with Pseudobulbar Affect (PBA)

Onscreen Text: Getting Diagnosed with Pseudobulbar Affect (PBA).

Patient images reflect their health status at the time the video was taken. The following are real patients and caregivers who have been compensated by Otsuka America Pharmaceutical, Inc., for their time.

Onscreen Text:

Getting diagnosed with PBA can be challenging because it is often mistaken for other conditions.

Onscreen Text:

Some patients struggle for months or years because PBA is commonly misdiagnosed and may go unrecognized.

Onscreen Text:

Mary Beth Living with Epilepsy and PBA

Mary Beth: When I started to have these conversations with my doctors there was always the input from them that this was // you know, it was depression, it was uh.. maybe a mood disorder, uhm.. and if I could get over my depression the crying would stop.

Onscreen Text:

Carol Living with PBA due to TBI

Carol:

After about three months after my injury and I felt I was no better, n- nothing was changing then that's when I started to document things, the number of episodes per day, uhm.. pretty much down to the time that they started. // I thought maybe somewhere I would have some hidden nugget of information that would click with somebody and help me get a diagnosis.

Onscreen Text:

Sequena Living with Stroke and PBA

Sequena: I was confused because they were telling me that I had depression // they were prescribing me antidepressants, but yet I was still crying all the time. // It had to be something else. And so that's when I started to research myself, and then that's also when I saw a commercial // and it was just like oh my gosh, that's what I got, like that's what I have.

Carol: The neurologist made the diagnosis based on uhm.. watching me walk, uh.. asking me questions, uhm.. I was in a full-blown crying episode right in front of him, uh.. but he knew the questions to ask. He knew to differentiate between my crying and my actual mood. He tuned right into that.





Mary Beth: My neurologist when she told me it was PBA uh.. I just I think she could read the sigh of relief on my face. // Finally after all this time I <crying> I'm not lying, I'm not making it up, I'm not exaggerating, I'm just, you know, struggling with the condition that I don't have control over and uhm.. it- it was just uh.. like a light, you know, now it was real.

Onscreen Text:

Liyah Caregiver for her mother Sequena

Liyah: Once you have a diagnosis, it's like from there, it gives you hope that now that we know what it is, we can move forward and begin taking steps. Because when you don't know what it is, it's like how do you even take steps forward. But when you get this diagnosis, it was like, this hope came back.

Sequena: What I would say to a person that is experiencing...// uncontrollable crying or laughing is to speak with your doctor about PBA.

Onscreen Text:

Talk to a healthcare specialist experienced in treating PBA

PBA is treatable

Please keep watching for NUEDEXTA Indication and IMPORTANT SAFETY INFORMATION.

Onscreen Text and Narrator:

INDICATION and IMPORTANT SAFETY INFORMATION for NUEDEXTA® (dextromethorphan HBr and quinidine sulfate)

INDICATION:

NUEDEXTA is approved for the treatment of Pseudobulbar Affect (PBA).

PBA is a medical condition that causes involuntary, sudden, and frequent episodes of crying and/or laughing in people living with certain neurologic conditions or brain injury. PBA episodes are typically exaggerated or don't match how the person feels. PBA is distinct and different from other types of emotional changes caused by neurologic disease or injury.

NUEDEXTA is only available by prescription.

IMPORTANT SAFETY INFORMATION:

Before you take NUEDEXTA, tell your doctor:

- If you are taking monoamine oxidase inhibitors (MAOIs), quinidine, or quinidine-related drugs. These can interact
 with NUEDEXTA causing serious side effects. MAOIs cannot be taken within 14 days before or after taking
 NUEDEXTA.
- · If you have previously had an allergic reaction to dextromethorphan, quinidine or quinidine-like drugs.



- About all medicines, herbal supplements, and vitamins you take as NUEDEXTA and certain other medicines can interact causing side effects.
- If you have had heart disease or have a family history of heart rhythm problems. NUEDEXTA may cause serious side effects, including changes in heart rhythm. If you have certain heart problems, NUEDEXTA may not be right for you. Your doctor may test your heart rhythm (heartbeats) before you start NUEDEXTA.
- If you have myasthenia gravis.

While taking NUEDEXTA, call your doctor right away:

- If you feel faint or lose consciousness.
- If you experience lightheadedness, chills, fever, nausea, or vomiting as these may be signs of an allergic reaction to NUEDEXTA. Hepatitis has been seen in patients taking quinidine, an ingredient in NUEDEXTA.
- If you have unexplained bleeding or bruising. Quinidine, an ingredient in NUEDEXTA, can cause a reduction in the number of platelets in your blood which can be severe and, if left untreated, can be fatal.
- · If you feel dizzy, since it may increase your risk of falling.
- If you have muscle twitching, confusion, high blood pressure, fever, restlessness, sweating, or shivering, as these may be signs of a potential drug interaction called serotonin syndrome.

The most common side effects of NUEDEXTA include: diarrhea, dizziness, cough, vomiting, weakness, and swelling of feet and ankles. This is not a complete list of side effects. Tell your doctor about any side effect that bothers you or does not go away.

You are encouraged to report side effects of NUEDEXTA® (dextromethorphan HBr and quinidine sulfate). Please contact Otsuka America Pharmaceutical, Inc. at 1-800-438-9927 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Please see FULL PRESCRIBING INFORMATION at www.NUEDEXTA.com

Onscreen Text:

PBA is treatable
Talk to a healthcare specialist experienced in treating PBA
[NUEDEXTA logo]

Onscreen Text:

© 2024 Otsuka America Pharmaceutical, Inc. All rights reserved. NUEDEXTA® is a registered trademark of Avanir Pharmaceuticals, Inc. and used under license by Otsuka America Pharmaceutical, Inc. April 2024 18US24EBC0036

